Characteristics of suboptimal immune response after initiating antiretroviral therapy among people living with HIV with a pre-treatment CD4 T cell count <200 cells/mm³ in Thailand

Win Min Han a, Sasiwimol Uboiyam a, Tanakorn Apornpong a, Stephen J. Kerr a,b,c, Pokrath Hansasuta d, Sivaporn Gatechompol a,e, Wirach Maekanantawat a, Kiat Ruxrungtham a,f, Praphan Phanuphak a, Jintanat Ananworanich g,i, Anchalee Avihingsanon a,v,

a The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
b Biostatistics Excellence Centre, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
c The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia
d Division of Virology, Department of Microbiology, Chulalongkorn University, Bangkok, Thailand
e Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
f Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
g SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
h Department of Global Health, University of Amsterdam, Amsterdam, the Netherlands

ARTICLE INFO

Keywords:
Suboptimal immune recovery
Immune characteristics
Antiretroviral treatment
Asian

ABSTRACT

Background: Complete recovery of the CD4 T cell count is uncommon among chronically HIV-infected individuals with very low pre-treatment CD4 count. We studied the prevalence of chronically immune recovery and its associated factors including immune characteristics chronic HIV-infected Thais.

Methods: Treatment-naïve participants (n = 375) from the HIV-NAT 006 cohort with a pre-treatment CD4 T cell count after initiating antiretroviral therapy (ART) and having achieved a suppressed viremia (HIV-RNA level < 400 copies/mL) were retrospectively followed at the Thai Red Cross AIDS Research Centre, Bangkok, Thailand. Suboptimal immune recovery (SIR) was defined as having a CD4 T cell count <200 cells/mm³ for 3 years after ART initiation. A case-control sub-study matched for age, sex and pre-ART CD4 T cell count was conducted to compare immunological characteristics between SIR (n = 17) and non-SIR (n = 24) participants. Immunological biomarkers such as interleukin-7 (IL-7) and soluble CD14 (sCD14) and other covariates including cytomegalovirus (CMV) DNA level, baseline hemoglobin level, hepatitis B and C co-infections, and T cell subsets associated with immune activation and exhaustion were evaluated.

Results: Among 375 participants with pre-ART CD4 T cell counts < 200 cells/mm³, the prevalence of SIR was 39.7%, 19.7% and 7.7% at years 1, 2 and 3 after starting ART, respectively. In a multivariate analysis, a pre-ART CD4 T cell count <200 cells/mm³ (adjusted odds ratio [aOR] 9.45, 95% CI 2.92–30.61, p < 0.001), older age (aOR 1.07, 95% CI 1.01–1.13, p = 0.029) and baseline HIV-RNA level (aOR 0.36, 95% CI 0.21–0.59, p < 0.001) were independently associated with SIR at year 3 after ART initiation. In the matched case-control sub-study (cases = 17, controls = 24), there was a higher prevalence of hepatitis C co-infection (18.8% vs. 0%, p = 0.05), lower sCD14 levels (mean, 6.23 vs. 6.27 log10 pg/mL, p = 0.04), lower CD8 T cell counts (mean, 514 vs. 876, p = 0.0003), lower CD4/CD8 T cell ratio (mean, 0.27 vs. 0.41, p = 0.01) and higher expression of PD1 on CD8⁺ T cells (74.2% vs. 65.1%, p = 0.02) observed in SIR participants compared to their non-SIR counterparts at year 3 after ART initiation.

Conclusions: Nearly 10% of the study participants who had achieved virological suppression failed to recover a CD4 T cell count > 200 cells/mm³ after 3 years of ART which was with a very low pre-ART CD4 T cell count and older age. The long-term clinical outcomes of SIR participants need to be further explored.
1. Background

The human immunodeficiency virus (HIV) depletes CD4+ T cells, which is the major contributing factor leading to the acquired immunodeficiency syndrome (AIDS). Early initiation of combination antiretroviral therapy (ART) is associated with lower mortality and reduced incidence of AIDS events among people living with HIV (PLHIV). Since 2015, the World Health Organization (WHO) guidelines recommend initiating ART regardless of the CD4 T cell count based on strong evidence of the benefit of early ART initiation. Globally, the overall improvement in the quality of HIV diagnosis and treatment has dramatically halted serious AIDS-related deaths and reduced transmission in the past decades. However, in many settings, a subset of PLHIV frequently present with late stage disease and have a low CD4 T cell count when they test. Therefore, ART is initiated in the context of advanced disease and extremely low CD4 T cell counts. These late presenters suffer from opportunistic infections and premature death.

Early ART initiation improves the CD4 T cell count recovery, immune function, and longevity among PLHIV; however, a certain number of individuals on ART fail to restore their immune function even after achieving virological suppression. There are several CD4 T cell cut-off levels to indicate suboptimal immune recovery (SIR) post-ART. Since a CD4 T cell count has clinical implications and is associated with AIDS and non-AIDS defining illnesses, we used this CD4 T cell level as the cut-off to indicate SIR. The frequency of SIR ranges from 15-30% and is associated with old age, male sex, low nadir CD4 T cell count and persistent immune activation.

The causal link between HIV-associated persistent inflammation/immune activation and disease progression, especially among chronically HIV-infected patients with low CD4 T cell counts, has been previously studied. Higher levels of soluble CD14 (sCD14) have been shown to be associated with all-cause mortality in PLHIV. Plasma interleukin-7 (IL-7) levels, a gamma chain receptor cytokine for the regulation of CD4+ and CD8+ T-cells, have been suggested to be negatively correlated with the CD4 T cell count and predictive of HIV disease progression. The normalization of CD4/CD8 ratio has been suggested to be a biomarker for immune dysfunction. PLHIV with low CD4 T cell counts and a low CD4/CD8 T cell ratio are at higher risk for developing AIDS-related and non-AIDS events. Moreover, a previous study showed that higher CD38 expression was also independently associated with reduced survival despite HIV virological suppression, suggesting that immune activation in PLHIV contributes to disease progression.

Unlike other regions, data regarding immune recovery are limited in the Asia region. Although current guidelines recommend ART initiation regardless of the CD4 T cell count, advanced disease and late presentation are still common in this part of the world. Therefore, it is important to better understand the characteristics and outcomes of PLHIV presenting with a low CD4 T cell count and those with persistent SIR after ART initiation. In this study, we investigated the prevalence of SIR with a CD4 T cell count less than 200 cells/mm3 after 3 years of initiating ART and its associated factors including immune characteristics among HIV-infected Thais.

2. Methods

2.1. Study participants

Data from ART-naive HIV-infected adults aged ≥18 years old who were enrolled between 2011 to 2013 into the HIV NAT 006 (the Netherlands-Australia and Thailand collaboration in HIV research) a long-term follow-up HIV cohort in Bangkok, Thailand, were analyzed. ART was initiated at enrollment. Sociodemographic and HIV-related variables such as age, sex, types of ART regimen, HIV-RNA level, CD4 T cell counts and baseline clinical events (including opportunistic infections and tuberculosis) were collected.

2.2. Definitions of suboptimal immune recovery and other variables

In this analysis, we have defined SIR as a CD4 T cell count < 200 cells/mm3 after 3 years of successful ART with suppressed HIV viremia (HIV RNA levels ≤ 400 copies/mL). Hepatitis B (HBV) co-infection was defined as having a positive hepatitis B surface antigen. Hepatitis C (HCV) co-infection was defined by the detection of HBS antigen. HCV co-infection was defined by the presence of HCV antibodies confirmed by HCV viremia. HCV antibodies were tested with a third generation CMIA (ARCHITECT system, Abbott Diagnostics, Wiesbaden, Germany). To confirm HCV infection we quantified HCV RNA with RealTime PCR (m2000 system, Abbott Molecular, Inc., Des Plaines, IL, USA).

2.3. Markers of immune activation, T cell subsets and co-infections

Immunological parameters such as the CD4/CD8 T cell ratio, IL-7, sCD14 and immune-phenotyping were determined in a cross sectional sub-study of a smaller sample size (cases = 17, controls = 24) at year 3 after initiating ART. Cases were defined as participants with < 200 CD4 T cells/mm3 CD4 T cell and controls as those with > 200 CD4 T cells/mm3 CD4 T cell count. Cases and controls were matched by age, sex and pre-ART CD4 T cell. Ages were classified into 5 categories, ≤30, 31-35, 36-40, 41-45, 46-50 years old (five-year age bands). In terms of the CD4 T cell count, it was classified into 4 categories, <50, 50-100, 100-150, 150-200 (50 cells/mm3 CD4 T cell bands). Cases were matched to controls with matching variables. Available stored samples at the time of analysis were included into this sub-study. Site investigators reviewed the selection process.

Frozen peripheral blood mononuclear cells (PBMC) were analyzed using flow cytometry. Cells were stained and analyzed to determine the proportion of CD4+ and CD8+ T cells using 8-colour flow cytometry (FACS Diva, BD Biosciences). T cell maturation subsets such as naïve (T N, CD45RA+CCR7+), central memory (T CM, CD45RA-CCR7+), and transitional memory (T TM, CD45RA-CCR7-) cells. Activated phenotypes of CD4+ and CD8+ T cells were also determined by the proportion of CD38 and HLA-DR (CD4+CD38+HLA-DR+, and CD8+CD38+HLA-DR+) cells. T cell exhaustion was determined by the percentage of programmed death-1 (PD-1) expression on both CD4+ and CD8+ T cells. Cryopreserved plasma was further tested by immunoenassay for IL-7 (R&D Systems, Minneapolis, MN, USA) and sCD14 (R&D Systems, Minneapolis, MN, USA). All participants were tested for co-infections such as cytomegalovirus (CMV) HBV and HCV infections. (CMV), HBV and HCV. CMV DNA polymerase chain reaction (PCR) tests were performed (Roche Molecular Systems, NJ, USA) using plasma samples. The assay used had a CMV DNA limit of detection (LOD) of 44 copies/mL.

2.4. Statistical analysis

Baseline characteristics including age, sex, mode of transmission, body mass index (BMI), pre-ART CD4 T cell count, HIV-RNA level and Centers for Disease Control and Prevention (CDC) HIV staging were compared between participants with or without SIR. Continuous variables were expressed as median (interquartile range, IQR). Differences in continuous and categorical variables between SIR and non-SIR groups were assessed using a Wilcoxon rank sum test and chi-square-test, respectively. The prevalence of SIR among study participants with virological suppression was described at years 1, 2 and 3 after initiating ART. Predictors of SIR were explored by using univariate analysis and then further tested by immunoassay for IL-7 (R&D Systems, Minneapolis, MN, USA) and sCD14 (R&D Systems, Minneapolis, MN, USA). All participants were tested for co-infections such as cytomegalovirus (CMV) HBV and HCV infections. (CMV), HBV and HCV. CMV DNA polymerase chain reaction (PCR) tests were performed (Roche Molecular Systems, NJ, USA) using plasma samples. The assay used had a CMV DNA limit of detection (LOD) of 44 copies/mL.
2.5. Ethical considerations

All participants gave informed consent. This cohort study was reviewed and approved by the Institutional Review Boards of the Faculty of Medicine, Chulalongkorn University in Bangkok, Thailand.

3. Results

3.1. Participant characteristics

A total of 375 participants who had been treated with ART for ≥3 years were recruited into the study. Baseline characteristics are described in Table 1. The overall median age of participants was 34 (IQR, 30–40) years with median pre-ART CD4 T cell counts of 74 (IQR, 27–131) cells/mm³, 21.3% of participants had CDC stage C. The median baseline HIV-RNA level was 4.8 (IQR, 4.3–5.3) log₁₀ copies/mL. Among study participants, 151 (41.7%) and 159 (43.9%) of them initiated treatment with non-nucleotide reverse transcriptase inhibitors (NNRTI)-based and protease inhibitors (PI)-based regimens, respectively. Proportions of the participants with baseline HBV and HCV co-infections were 20.6% and 6.3%, respectively. 51 (24.5%) participants had detectable CMV DNA levels in the non-SIR group compared to the SIR group (0%).

3.2. Prevalence and factors associated with SIR at 3 year after initiating ART

The prevalence of SIR was 39.73%, 19.7% and 7.73% at years 1, 2 and 3 after starting ART, respectively. The CD4 and CD8 T cell counts and CD4/CD8 T cell ratio of participants with SIR and non-SIR at year 1, year 2 and year 3 are described in Fig. 1. Participants in the SIR group had a lower pre-ART CD4 T cell count compared to the non-SIR group (44, IQR, 18–72 vs. 79, IQR, 27–134, p = 0.003) at year 3 after initiating ART. Three years after initiating ART, participants with SIR had significantly lower median CD4 T cell counts (161, IQR, 133–181 vs. 375, IQR, 302–490 cells/mm³, p < 0.001) compared to the participants with non-SIR. Moreover, the participants with SIR had lower median CD4/CD8 ratio compared to their counterparts at 3 years after initiating cART (0.24, IQR, 0.2–0.33 vs. 0.45, IQR, 0.35–0.63, p < 0.001) (see Fig. 2).

At year 3 after initiating ART, male sex, older age, and pre-ART CD4 T cell count < 100 cells/mm³ (vs. ≥100 cells/mm³) were associated with SIR in the univariate analysis (Table 2). Baseline HIV-RNA level was negatively associated with SIR. After adjusting for confounders from the univariate analysis, older age (aOR 1.07, 95% CI 1.01–1.13, p = 0.029), and a pre-ART CD4 T cell count < 100 cells/mm³ (aOR 9.45, 95% CI 2.92–30.61, p < 0.001, vs. ≥100 cells/mm³) were independently associated with SIR.

Table 1

Participants’ baseline characteristics.

|                            | Suboptimal Immune Response, SIR (n = 29) | Non-SIR (n = 346) | Total (n = 375) | P-value |
|---------------------------|----------------------------------------|-------------------|----------------|--------|
| **Sex, n (%)**            |                                        |                   |                |        |
| Female                    | 7 (24.1)                               | 156 (45.1)        | 163 (43.5)     | 0.029  |
| Male                      | 22 (75.9)                              | 190 (54.9)        | 212 (56.5)     |        |
| **Age in years, median (IQR)** |                                     |                   |                |        |
|                           | 38 [34–44]                             | 34 [30–40]        | 34 [30–40]     | 0.015  |
| **BMI, median (IQR)**     |                                        |                   |                |        |
|                           | 19.3 (17.9–21.9)                       | 20.5 (18.5–22.6)  | 20.5 (18.5–22.5)| 0.31   |
|                           | N = 11                                 | N = 180           | N = 191        |        |
| **Pre-ART CD4 cell count, cells/mm³, median (IQR)** | | | | |
|                           | 50 (34–151)                            | 100               | 89 (33–148)    | 0.005  |
| **Pre-ART HIV-RNA, log₁₀ copies/mL, median (IQR)** | | | | |
|                           | 4.5 (4.2–4.8)                          | 4.8               | 4.8            | 0.012  |
|                           | N = 11                                 | N = 180           | N = 191        |        |
| **CDC clinical staging, n (%)** |                                      |                   |                | 0.44   |
| A                         | 7 (24.1)                               | 122 (35.3)        | 129 (34.4)     |        |
| B                         | 14 (48.3)                              | 152 (43.9)        | 166 (44.3)     |        |
| C                         | 8 (27.6)                               | 72 (20.8)         | 80 (21.3)      |        |
| **CMV DNA, copies/ml, n (%)** |                                    |                   |                | 0.002  |
| ≥44 (lower limit of detection) | 26 (100.00)                           | 157 (75.5)        | 183 (78.2)     |        |
| ≥44                       | 0 (0.00)                               | 51 (24.5)         | 51 (21.8)      |        |
| Hepatitis B coinfection, n (%) | 6 (21.4)                        | 61 (20.5)         | 67 (20.6)      | 0.90   |
| Hepatitis C coinfection, n (%) | 3 (11.1)                        | 18 (5.8)          | 21 (6.3)       | 0.23   |

Fig. 1. The graphs show CD4 (1 A), CD8 (1 B) T cell counts and CD4/CD8 (1 C) recovery among participants with suboptimal immune response (SIR) and non-SIR group.
associated with SIR at year 3 after initiating ART. Baseline HIV-RNA level (aOR 0.36, 95% CI 0.21–0.59, \( p < 0.001 \)) was negatively associated with SIR after adjusting for confounders from the univariate model. We did not find any significant association of viral hepatitis, baseline hemoglobin level and baseline CMV DNA levels with SIR at year 3 after initiating ART.

3.3. Immune activation and T-cell activation/exhaustion in the matched case-control sub-study

The characteristics of participants in the matched case-control sub-study are described in Table 3. At year 3 after initiating ART, all participants had a suppressed viral load. Immunological parameters were obtained from participants at year 3 after initiating ART. In the matched case-control sub-study (SIR = 17, non-SIR = 24), participants from the SIR group had significantly lower CD8 T cell counts (719 [95% CI, 604–834] vs. 920 [95% CI 614–1226], \( p = 0.003 \)) and CD4/CD8 T cell ratios. (0.27 [95% CI, 0.22–0.37] vs. 0.41 [95% CI, 0.29–0.51], \( p = 0.01 \)) compared to the non-SIR group. None of the participants had detectable CMV DNA level at year 3 after initiating ART. However, participants from the SIR group had lower sCD14 levels than those from the non-SIR group (6.23 IQR, 6.18–6.27 vs. 6.27 IQR, 6.21–6.39 log10 pg/mL, \( p = 0.03 \)). There was no statistical difference in IL-7 levels between the two groups. Additionally, analysis of T cell subsets showed significant higher levels of CD8\(^+\) T\(_{TM}\) cell exhaustion (CD8\(^+\)-CCR7-CD45RA-PD1\(^+\), 74.2% vs. 65.1%, \( p = 0.02 \)) among participants in the SIR group at year 3 after initiating ART. We did not find any significant differences in T cell activation levels between the two groups. Detailed results of the immune activation and exhaustion markers of T cells are described in the supplemental table (Table S1).

4. Discussion

This study shows that nearly 10% of study participants who had achieved virological suppression had SIR with a CD4 T cell count <200 cells/mm\(^3\) after continuous ART for 3 years. The prevalence of SIR was 39.73%, 19.7% and 7.73% at years 1, 2 and 3 after starting ART, respectively. The frequency of SIR from this Thai cohort is comparable to that of SIR after 24 months of ART in an urban cohort from Sub-Sahara Africa after 24 months that used the same CD4 T cell threshold criteria of <200 cells/mm\(^3\).\(^{12}\)

SIR participants at year 3 after initiating ART were older, had a lower nadir CD4 T cell count and at year one after ART initiation together with a lower HIV-RNA at baseline. From the multivariate analysis, factors associated with SIR included older age, lower CD4 T cell counts and HIV-RNA level at ART initiation. Previous studies have also shown that age is a predictor of SIR,\(^{31,32}\) even among participants with virological suppression.\(^{8}\) The association of age and SIR with good virological response is possibly due to failing thymic T cell production.\(^{8}\) We did not find an association of viral hepatitis infections (HBV and HCV) with SIR at year 3 after initiating ART. This finding is consistent with a report that showed that neither HBV co-infection or HBeAg reactivity had any impact on CD4 T cell recovery while on ART.\(^{33}\)

The prevalence of SIR varied according to different settings.\(^{34}\) For
example a study from sub-Saharan Africa reported nearly 15% participants with SIR (using CD4 <200 cells/mm$^3$) at 3 years and 7% at 6 years post-ART initiation. This current study showed 7% the predictive value of a low CD4 T cell count at ART initiation. In addition, multiple studies have shown a nearly 8% SIR prevalence after 3 years of ART initiation and how it affects the long-term immune recovery of PLHIV. A low baseline CD4 T cell count (<100 cells/mm$^3$) is a strong predictor for SIR in our study. This is in line with the report from the Swiss HIV cohort study which showed that the baseline CD4 T cell count independently predicted the incomplete immune response (defined by CD4 T cell count recovery of <500 cells/mm$^3$) 5 years after initiating ART. The study also showed that the annual increase in the CD4 T cell count was relatively smaller in immunological non-responders compared to their counterparts.

We also found that the baseline HIV-RNA level was negatively correlated with SIR despite the fact that all participants had viral suppression at year 3 after initiating ART. This result is consistent with a recent modelling study that assessed the CD4 recovery over the years after ART initiation; a higher HIV viral load at ART initiation was strongly associated with a higher level of CD4 T cell recovery. Previous studies have suggested that a high pre-treatment HIV viral load was a predictor of rapid CD4 T cell recovery because the sequestered T cells may be in higher numbers within the lymphoid tissues in a context of uncontrolled viral replication and could be released quickly into the circulation after ART initiation.

In our study, baseline CDC grade B or C events were not associated with SIR at year 3 after initiating ART. A previous report showed that 21% of incomplete responders developed clinical CDC grade B or C events but there was no difference in terms of AIDS events between incomplete and complete responders. However, in our study, we could not evaluate whether there were any differences in AIDS-related events among participants with and without SIR after initiating ART because of the the small sample size was small.

The CD4/CD8 T cell ratio among SIR participants in the study was significantly lower than non-SIR participants at year 3 after ART initiation. Additionally, we also found that the the CD4/CD8 T cell ratio recovery was much slower in SIR participants (Supplementary Table S2). This finding indicates that there is a high level of immune activation among SIR participants; a previous study reported that the CD4/CD8 T cell ratio recovery was a surrogate marker for chronic inflammation and immune activation. We have recently reported that a low CD4/CD8 T cell ratio in the Thai cohort was associated with a lower baseline CD4 T cell count and could predict non-AIDS events after years of follow-up, even in a context of virological suppression. The SIR participants whose CD4/CD8 T cell ratio remained low after years of suppressive cART may have poor long-term prognosis such as a higher chance of developing non-AIDS related events and comorbidities. A longer follow-up study is needed.

We did not find a difference in the expression of activation markers (HLA-DR, CD38) on both CD4$^+$ and CD8$^+$ T cells between SIR and non-SIR participants. However, SIR participants had a higher expression of PD-1 on CD8$^+$ T cells which is in line with previous reports; PLHIV with low nadir CD4 T cells are immunologically not responsive because there is intrinsic T cell apoptosis. Surprisingly, sCD14 levels in our SIR participants were lower than in their non-SIR counterparts at year 3 after initiating ART despite the fact that all participants had undetectable CMV DNA levels. The levels of sCD14 among our study participants (both SIR and non-SIR) were higher than those of healthy HIV-negative Thais (median, 5.9; IQR 5.9–6.0 log$10$ pg/mL, n = 10) from a previous study.

Our study was limited by the relatively short duration of follow-up to evaluate CD4 T cell recovery. Second, the sample size of the matched case-control group was small so it was difficult to analyze immune predictors and other parameters for immune recovery, and other parameters. Third, the clinical significance in the difference of the various

### Table 2

| Variables for SIR | Univariate model$^1$ | Multivariate model | aOR | 95% CI | p-value |
|------------------|----------------------|--------------------|-----|--------|---------|
|                  | OR       | 95% CI | p-value | OR       | 95% CI | p-value |
| Male             | 2.58     | (1.07–6.20) | 0.034 | 1.96    | (0.78–4.94) | 0.155 |
| Age (years)      | 1.06     | (1.00–1.11) | 0.027 | 1.07    | (1.01–1.13) | 0.029 |
| Baseline CD4 count (vs. stage A/B) | 1.45 | (0.62–3.41) | 0.394 |       |       |     |
| BMI (kg/m$^2$)   | 0.92     | (0.76–1.10) | 0.348 |       |       |     |
| Pre-ART HIV-RNA level in log$10$ copies/mL | 0.54 | (0.36–0.81) | 0.003 | 0.36    | (0.21–0.59) | <0.001 |
| Pre-ART CMV DNA, copies/mL | 1.06 | (0.41–2.73) | 0.904 |       |       |     |
| Pre-ART HCV co-infection | 1.01 | (0.83–1.25) | 0.891 |       |       |     |
| Pre-ART HCV co-infection | 2.01 | (0.55–7.32) | 0.288 |       |       |     |

OR = odds ratio; CI = confidence interval; Hb = haemoglobin; BMI = body mass index; aOR = adjusted odds ratio.

$^1$ Covariates with p-value less than 0.1 were adjusted in the multivariate models.

### Table 3

| Immunological characteristics among SIR and non-SIR participants at year 3 after initiating ART. |
|-----------------------------------------------|
| Age, sex and baseline CD4 count matched case-control |
|                  | SIR | Non-SIR | P-value |
| Number of participants | N = 17 | N = 24 | 0.80 |
| Sex, n (%) |     |       |     |
| Female | 3 (17.7) | 5 (20.8) |       |
| Male | 14 (82.3) | 19 (79.2) |       |
| Age in years, median (IQR) | 36 (34–44) | 37(32–42) | 0.72 |
| BMI, median (IQR) | 20.6 | 21.1 | 0.70 |
| (19.3–21.9) | (19.7–24.2) |       |
| Pre-ART CD4 count cells/mm$^3$, median (IQR) | 4 (23.5) | 5 (20.8) | 0.837 |
| 100 | 13 (76.5) | 19 (79.2) |       |
| Pre-ART HIV-RNA level in log$10$ copies/mL, median (IQR) | 4.22 | 4.2–4.8 | 0.13 (4.6–5.6) | 0.003 |
| HBV co-infection, n (%) | 3/16 (18.8) | 10/20 (50.0) | 0.083 |
| HCV co-infection, n (%) | 3/16 (18.8) | 6/19 (0.00) | 0.05 |
| IL-7 <13 pg/mL, n (%) | 15 (88.2) | 17 (70.8) | 0.262 |
| sCD14 (log$10$pg/mL, mean (95% CI) | 6.23 | 6.27 | 0.04 |
| CD4/CD8 ratio, mean (95% CI) | 0.27 | 0.41 | 0.010 |
| (0.22–0.37) | (0.29–0.51) |       |
| CD68 count, mean (95% CI) | 514 | 876 | 0.0003 |
| (358-695) | (652–1127) |       |
| CD68+CCR7-CD45RA-PD1+, mean (95% CI) | 25.1 | 34.9 | 0.02 |
| (20.6–27.9) | (28.3–42.5) |       |
| CD68+CCR7-CD45RA-PD1+, mean (95% CI) | 74.2 | 65.1 | 0.02 |
| (70.5–78.7) | (57.2–70.3) |       |
| CMV DNA, copies/mL, n (%) | 17 (100.0) | 24 (100.0) | N/A |
| ≤44 (lower limit of detection) | 0 (0.0) | 0 (0.0) |     |
| >44 | 0 (0.0) | 0 (0.0) |     |
markers observed between SIR and non-SIR participants in the sub-study was remains uncertain, thus these differences should be interpreted clinically cautiously and further studies should explore the long-term clinical impact between the two groups. Nevertheless, our finding provides with an insight on the immunology of non-responders in an Asian population that was previously unavailable.

In conclusion, SIR after ART initiation is common among participants with a low baseline CD4 T cell count. Nearly 10% of study participants who had achieved virological suppression failed to recover a CD4 T cell count to >200 cells/mm³ after 3 years of ART which was associated with very low pre-ART CD4 cell counts (CD4 < 100 cells/mm³) and older age. We also found that SIR participants had low CD4/CD8 T cell ratios and high levels of T cell exhaustion. The long-term clinical outcomes of SIR participants need to be further investigated.

Funding

This work was supported by Rachadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University Code: RA 35-53. The funders had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript for publication.

Declaration of competing interest

A.A. Okoye received honoraria for consultation from Viiv Healthcare. KR received honoraria or consultation fees from Merck, Roche, Jensen-Cilig, Johnson & Johnson, Mylan and GPO (Governmental pharmaceutical organization, Thailand); has participated in a company sponsored speaker’s bureau from Abbott, Gilead, Bristol-Myers Squibb, Merck, Roche, Jensen-Cilig, Viiv Healthcare, and GPO (Governmental pharmaceutical organization); and received Chulalongkorn Academic Advancement into Its 2nd Century Project (CUAASC). AA has received honoraria for participating in advisory meetings from Viiv Healthcare, Merck, Gilead, Roche and Abb-Vie. The rest of the authors declare no conflict of interest.

Acknowledgements

We would like to thank all of the participants for their contribution to the study. We would also like to thank Pirapon June Ohata for editing the manuscript and the team of HIV-NAT 006 cohort for their hard work.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jve.2020.100005.

References

1. A.A. Okoye, L.J. Picker, CD4(+)-T-cell depletion in HIV infection: mechanisms of immunological failure, Immunol. Rev. 254 (1) (2013) 54-64.
2. D. Klatzmann, F. Barre-Sinoussi, M.T. Nugeyre, C. Danquet, E. Vilmer, C. Gréculle, et al., Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes, Science 225 (4657) (1984) 59.
3. H. Manz, F.P. Orubulue, R. Varchon, J.H. Shelhamer, B.F. Baird, W. Travis, et al., CD4 count as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection, Ann. Intern. Med. 111 (3) (1989) 223-231.
4. C. When To Start, Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies, Lancet 373 (9762) (2009) 1352-1363.
5. Initiation of antiretroviral therapy in asymptomatic HIV infection, N. Engl. J. Med. 373 (7) (2015) 795-807.
6. WHO, Guideline on when to Start Antiretroviral Therapy and on Pre-exposure Prophylaxis for HIV, WHO, Geneva, 2015.
7. A.N. Phillips, J.D. Lundgren, The CD4 lymphocyte count and risk of clinical progression, Curr. Opin. HIV AIDS 1 (1) (2006) 43-49.
8. L. Teixeira, H. Valdez, J.M. McCane, R.A. Koup, A.D. Badley, M.K. Hessler, et al., Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function, Aids 15 (14) (2001) 1749-1756.
9. F. Aiuti, L. Mezzaroma, Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART, AIDS Res. 8 (2) (2006) 88-97.
10. S.H. Tuboi, M.W. Brinkhof, M. Egger, R.A. Stone, P. Bräitstein, D. Nash, et al., Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration, J. Acquir. Immune Defic. Syndr. 45 (1) (2007) 52-59.
11. E. Florence, J. Lundgren, C. Dreezen, M. Fisher, O. Kirk, A. Blaxhult, et al., Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study, HIV Med. 4 (3) (2003) 255-262.
12. D. Nakansjo, A. Kiragga, F. Ibrahim, B. Castelnuovo, M.R. Kamya, P.J. Easterbrook, Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance, AIDS Res. Ther. 5 (2008) 23.
13. G.R. Kaufmann, H. Furrer, B. Ledergerber, L. Perrin, M. Opravil, P. Vernezza, et al., Characterization, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy, Clin. Infect. Dis. 43 (1) (2006) 361-372.
14. X. Anglaret, A. Minga, D. Galliard, T. Ouassa, E. Messou, B. Morris, et al., AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d’Ivoire, Clin. Infect. Dis. 54 (5) (2012) 714-723, an official publication of the Infectious Diseases Society of America.
32. G.R. Kaufmann, H. Furrer, B. Ledergerber, L. Perrin, M. Opravil, P. Vernazza, et al., Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy, Clin. Infect. Dis. 41 (3) (2005) 361–372.

33. L.H. Omland, N. Weis, P. Skinhoj, A. Laursen, P.B. Christensen, H.I. Nielsen, et al., Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study, HIV Med. 9 (5) (2008) 300–306.

34. F. Maggiolo, S. Leone, CD4⁺ T lymphocyte recovery in individuals with type 1 human immunodeficiency virus infection, Clin. Infect. Dis. 51 (4) (2010) 465–467.

35. S. Kroeze, P. Ondoa, C.M. Kityo, M. Siwale, S. Akanmu, M. Wellington, et al., Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa, Aids 32 (8) (2018) 1043–1051.

36. R.D. Moore, J.C. Keruly, CD4⁺ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression, Clin. Infect. Dis. 44 (3) (2007) 441–446.

37. J.J. Lok, R.J. Bosch, C.A. Benson, A.C. Collier, G.K. Robbins, R.W. Shafer, et al., Long-term increase in CD4⁺ T-cell counts during combination antiretroviral therapy for HIV-1 infection, Aids 24 (12) (2010) 1867–1876.

38. E.H. Geng, T.B. Neilands, R. Thiebaut, M.B. Bwana, D. Nash, R.D. Moore, et al., CD4¹ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa, Int. J. Epidemiol. 44 (1) (2015) 251–263.

39. O.T. Stirrup, A.J. Copas, A.N. Phillips, M.J. Gill, R.B. Geskus, G. Touloumi, et al., Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion, HIV Med. 19 (3) (2018) 184–194.

40. R.P. Bucy, R.D. Hockett, C.A. Derdeyn, M.S. Saag, K. Squires, M. Sillers, et al., Initial increase in blood CD4⁺ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues, J. Clin. Invest. 103 (10) (1999) 1391–1398.

41. I. Jarrín, N. Pantazis, J. Dalmau, A.N. Phillips, A. Olson, C. Mussini, et al., Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4⁺ T-cell recovery once HIV-1 suppression is achieved? Aids 29 (17) (2015) 2323–2333.

42. M. Diaz, D.C. Douek, H. Valdez, B.J. Hill, D. Peterson, I. Sanne, et al., T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment, Aids 17 (8) (2003) 1145–1149.

43. S. Serrano-Villar, S. Moreno, M. Fuentes-Ferrer, C. Sanchez-Marcos, M. Avila, T. Sainz, et al., The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery, HIV Med. 15 (1) (2014) 40–49.

44. W.M. Han, T. Apornpong, S.J. Kerr, A. Hiransuthikul, S. Gatechompol, T. Do, et al., CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV, AIDS Res. Ther. 15 (1) (2018) 13.

45. E. Negredo, M. Massanella, J. Puig, N. Perez-Alvarez, J.M. Gallego-Escuredo, J. Villarroya, et al., Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications, Clin. Infect. Dis. 50 (9) (2010) 1300–1308.

46. J. Anawaromnich, C.P. Sacdalan, S. Pinyakorn, N. Chomont, M. de Souza, T. Luksamenuk, et al., Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection, J. Virus. Erad. 2 (1) (2016) 43–48.